Hospital Archives - ChartAlert®

MAXHEALTH – Max Healthcare Institute – Q4 FY26 Earnings Call – 22-May-26

Max Healthcare’s topline growth hinges on non-onco scaling and greenfield execution, while margins face structural pressure from oncology mix shifts and ALOS volatility.

1–2 minutes

Also see: MAXHEALTH – Max Healthcare Institute – Q4 FY26 Financial Results – 21-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Oncology share stabilizes at 21–22% + Gurgaon breakeven in FY28.
Revenue grows 12–15% CAGR (ex-oncology: 15–18%) as digital/international offset oncology drag. EBITDA margins hover at 26–27% due to ALOS/labor cost lags. Free cash flow ~₹1,500 crore/year funds ₹1,200–1,500 crore annual capex, keeping net debt-to-EBITDA <1.2x.

APOLLOHOSP – Apollo Hospitals Enterprise – Q4 FY26 Earnings Call – 21-May-26

Apollo Hospitals’ topline growth hinges on new hospital ramp-up and digital scaling, while margins and bottomline depend on execution of HealthCo turnaround and capex discipline.

1–2 minutes

Also see: APOLLOHOSP – Apollo Hospitals Enterprise – Q4 FY26 Financial Results – 20-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Drivers: New hospitals break even by FY28 at 50–55% occupancy, digital breakeven in Q3 FY27 (incl. ESOP), and HealthCo margins reach 6.5%. Capex remains disciplined (INR 1,550 crore redeployable), and insurance revenue grows 15–20% YoY. Topline: 15–18% revenue CAGR; Bottomline: PAT CAGR ~25%; Margins: Healthcare Services EBITDA ~25.5%, HealthCo 6.5%.

MAXHEALTH – Max Healthcare Institute – Q4 FY26 Financial Results – 21-May-26

Max Healthcare’s FY26 delivered 19% revenue and 34% PAT growth on ₹700 Cr+ base, confirming leverage in motion. Risks: near‑zero FCF and deteriorating receivables. FY27 re‑rating hinges on receivable discipline and debt‑to‑EBITDA as capex peaks; margin expansion and OCF strength keep structural story intact.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 19.1% YoY (₹7,02,846L → ₹8,37,345L), compounding on a large base — scale is not diluting growth velocity.
Q4FY26 revenue at ₹2,14,289L grew 12.2% YoY (vs ₹1,90,974L Q4FY25) and 3.6% QoQ — sequential momentum intact.
No segment data provided, but the pace of capacity addition (PPE up ₹1,49,712L YoY) signals the topline engine is being actively fuelled.

Bottomline

PAT grew 34.1% YoY (₹1,07,588L → ₹1,44,241L) — bottomline growing nearly 1.8x faster than revenue, confirming strong operating leverage.
Effective tax rate dropped sharply: 23.5% in FY26 vs 23.5% in FY25 headline-level, but FY25 included a deferred tax credit (₹562L) vs FY26 deferred charge (₹2,186L), masking an underlying cash tax improvement.
Q4FY26 PAT at ₹34,222L grew 7.3% YoY (vs ₹31,900L Q4FY25) — solid, though Q4FY25 had a higher current tax outflow (₹7,213L vs ₹5,858L), flattering the comparison.

Margins

EBITDA proxy (PBT before exceptional + D&A + Finance costs): FY26 = ₹1,72,382L + ₹44,653L + ₹23,510L = ₹2,40,545L on revenue of ₹8,37,345L → EBITDA margin ~28.7% vs FY25: (₹1,48,000L + ₹35,942L + ₹16,502L) / ₹7,02,846L = ₹2,00,444L → ~28.5% — margins essentially flat despite revenue scale-up.
Net profit margin: ₹1,44,241L / ₹8,37,345L = 17.2% vs ₹1,07,588L / ₹7,02,846L = 15.3% — 190bps expansion, driven by operating leverage on fixed costs.
Finance costs surged 42.5% YoY (₹16,502L → ₹23,510L), partially offsetting operating gains; bears watching as debt expands with capex.

Growth Trajectory

Revenue CAGR implied over FY25–26 at 19.1% on a ₹700Cr+ base is exceptional for a hospital network — pricing power + volume both contributing.
PAT growing at 34% with EBITDA flat suggests the leverage point is below EBITDA: D&A and finance costs are scaling, but PBT-to-PAT conversion is improving.
Capacity buildout (CWIP conversion + fresh PPE additions) suggests FY27 will test whether new beds can ramp revenues fast enough to sustain margin trajectory.

APOLLOHOSP – Apollo Hospitals Enterprise – Q4 FY26 Financial Results – 20-May-26

Apollo Hospitals’ FY26 delivered 33% PAT on 16% revenue growth, with Digital Health turning profitable — a margin expansion catalyst compressing EV/EBITDA. Net debt/EBITDA ~0.9x, but current borrowings spike and opaque acquisition need scrutiny. FCF ~₹8,937 Mn confirms self‑funding; FY27 watch is debt structure and capex intensity.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 15.8% YoY (₹217,940 Mn → ₹252,285 Mn), with all three core segments contributing — Healthcare Services (+13.6%), Retail Health & Diagnostics (+20.1%), and Digital Health & Pharmacy (+18.9%).
Q4FY26 revenue at ₹66,055 Mn grew 18.1% YoY over Q4FY25 (₹55,922 Mn), maintaining strong sequential momentum.
Digital Health & Pharmacy is now 43% of consolidated revenues, cementing its role as the volume engine.

Bottomline

PAT grew 33.1% YoY (₹15,051 Mn → ₹20,027 Mn), significantly outpacing revenue growth — a clear sign of operating leverage kicking in.
Basic EPS jumped from ₹100.56 to ₹135.04 (+34.3% YoY), reflecting earnings accretion without dilution.
Q4FY26 PAT of ₹5,513 Mn grew 33% YoY over Q4FY25 (₹4,145 Mn), sustaining the annual acceleration trend.

Margins

EBITDA proxy (PBT + Finance costs + D&A): FY26 = ₹26,609 + ₹4,496 + ₹8,761 = ₹39,866 Mn on revenues of ₹252,285 Mn → EBITDA margin ~15.8% vs FY25 (₹20,391 + ₹4,585 + ₹7,575 = ₹32,551 Mn on ₹217,940 Mn) → ~14.9%. Margin expanded ~90 bps YoY.
Net profit margin: FY26 = 7.9% vs FY25 = 6.9% — 100 bps expansion, driven by Digital Health segment swinging to meaningful profitability (₹1,127 Mn → ₹3,987 Mn segment result).
Retail Health & Diagnostics segment result nearly tripled (₹300 Mn → ₹723 Mn), adding further margin uplift.

Growth Trajectory

Three-year compounding is clearly accelerating: PAT grew 33% this year versus revenue growth of 16% — bottomline is finally outrunning topline.
Digital Health segment results surged 254% YoY (₹1,127 Mn → ₹3,987 Mn), signalling a structural shift from investment phase to profit contribution.
Segment result margin for Healthcare Services: FY26 = 24,303/127,501 = 19.1% vs FY25 = 21,295/112,201 = 19.0% — core hospital margins holding steady while adjacencies scale.

APOLLOHOSP – Q3 FY26 Earnings Call – 11-Feb-26

Apollo Hospital’s topline likely grows 12–15% in FY’27 (existing hospitals + phased bed additions), but bottomline faces 100–150 bps margin compression from new hospitals; digital profitability and Keimed synergies are binary catalysts for re-rating or de-rating.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key variables: 50% of 750 beds operational by FY’27, digital cash EBITDA breakeven in Q1 FY’27, and 3% pricing power in CONGO-T.
Outcome: Revenue grows 12–14%, EBITDA margins flat YoY (new hospital losses offset by existing hospital expansion). Keimed synergies partially realized; pharmacy delivers 18% same-store growth. Implication: EPS grows 10–12%; FCF breakeven in FY’28.

MAXHEALTH – Q3 FY26 Earnings Call – 6-Feb-26

Max Healthcare’s topline growth (12–15%) hinges on capacity absorption and CGHS normalization; bottomline expansion (100–150 bps EBITDA margin) requires payor mix distillation and brownfield ROCE delivery.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key variables: CGHS rate hikes materialize (Q1 FY’27); Gurgaon Phase 1 commissions by H1 FY’27; clinician retention stable.
Outcome: Revenue grows 12–15% YoY (capacity + ARPOB); EBITDA margins expand 100–150 bps to 27–28% by FY’28. Net debt/EBITDA remains <1x.